Trial Profile
Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Mar 2020
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Doxorubicin liposomal (Primary) ; Interferon; Thalidomide
- Indications Multiple myeloma; Plasma cell leukaemia
- Focus Therapeutic Use
- 21 Sep 2011 Additional lead trial centres identified as reported by ClinicalTrials.gov.
- 21 Sep 2011 Additional lead trial centres identified as reported by ClinicalTrials.gov.
- 08 Apr 2011 New trial record